Summary
In the last few years, genomic tools have been incorporated in natural product approaches to drug discovery, including understanding mechanisms of action which cannot be elucidated from phenotypic screens such as cell viability assays. The characterization of perturbed biological pathways and target identification are important for the evaluation of the compounds’ potential as drug leads and for subsequent medicinal chemistry efforts; however, general procedures to tackle this task are lacking. The combination of high-throughput screening and genomic-scale assays has proven to be a powerful tool to aid in the identification of mechanisms and potentially of protein targets, not only in yeast but also mammalian cells. Arrayed libraries of cDNAs can be transfected into cancer cell lines in a high-throughput fashion to generate variants of spatially separated cancer cells with increased gene dosages for one particular cDNA. Cells overexpressing gene products that are directly targeted by a small molecule or that lie in the perturbed pathway may be less susceptible to the effects of the compound. This fact provides the basis for drug susceptibility screens employing cDNA libraries. The general procedures to optimize and execute those screens and subsequently validate putative screening hits are discussed in detail.
Key words
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Stone, M. J. and Williams, D. H. (1992) The evolution of functional secondary metabolites (natural products). Mol. Microbiol. 6, 29–34
Dixon, N., Wong, L. S., Geerlings, T. H., and Micklefield, J. (2007) Cellular targets of natural products. Nat. Prod. Rep. 24, 1288–1310
Paterson, I. and Anderson, E. A. (2005) The renaissance of natural products as drug candidates. Science 310, 451–453
Breinbauer, R., Vetter, I. R. and Waldmann, H. (2002) From protein domain to drug candidates. Angew. Chem. Int. Ed. 41, 2878–2890
Kramer, R. and Cohen, D. (2004) Functional genomics to new drug targets. Nat. Rev. Drug Discov. 3, 965–972
Balunas, M. J. and Kinghorn, A. D. (2005) Drug discovery from medicinal plants. Life Sci. 78, 431–441
Newman, D. J. and Cragg, G. M. (2007) Natural products as sources of new drugs over the last 25 years. J. Nat. Prod. 70, 461–477
Butler, M. S. (2005) Natural products to drugs: natural product derived compounds in clinical trials. Nat. Prod. Rep. 22, 162–195
Shu, Y.-Z. (1998) Recent natural products based drug development: a pharmaceutical industry perspective. J. Nat. Prod. 61, 1053–1071
Newman, D. J. and Cragg, G. M. (2004) Marine natural products and related compounds in clinical and advanced preclinical trials. J. Nat. Prod. 67, 1216–1238
Baker, D. D., Chu, M., Oza, U., and Rajgarhia, V. (2007) The value of natural products to future pharmaceutical discovery. Nat. Prod. Rep. 24, 1225–1244
Lee, K.-H. (2004) Current developments in the discovery and design of new drug candidates from plant natural product leads. J. Nat. Prod. 67, 273–283
McChesney, J. D., Venkataraman, S. K., and Henri, J. T. (2007) Plant natural products: back to the future or into extinction? Phytochemistry 68, 2015–2022
Lam, K. S. (2007) New aspects of natural products in drug discovery. Trends Microbiol. 15, 279–289
Butler, M. S. (2004) The role of natural product chemistry in drug discovery. J. Nat. Prod. 67, 2141–2153
Atta-ur-Rahman, Choudhary, M. I., and, Thomsen, W. J. (eds.) (2001) Bioassay Techniques for Drug Development. Harwood Academic Publishers, Amsterdam
Rollinger, J. M., Langer, T., and Stuppner, H. (2006) Strategies for efficient lead structure discovery from natural products. Curr. Med. Chem. 13, 1491–1507
Potterat, O. and Hamburger, M. (2006) Natural products in drug discovery – concepts and approaches for tracking bioactivity. Curr. Org. Chem. 10, 899–920
Choma, I. (2005) The use of thin-layer chromatography with direct bioautography for antimicrobial analysis. LC-GC Eur. 18, 482–488
Bohlin, L. and Bruhn, J. G. (eds.) (1999) Bioassay Methods in Natural Product Research and Drug Development. Kluwer, Dordrecht, pp.119–142
Garipa, R. J. (2009) The emerging role of cell-based assays in drug discovery. In: Minor, L. K. (ed.) Handbook of Assay Development in Drug Discovery. CRC Press, Taylor & Francis Group, Boca Raton, FL, pp. 221–226
Gullo, V. P., McAlpine, J., Lam, K. S., Baker, D., and Petersen, F. (2006) Drug discovery from natural products. J. Ind. Microbiol. Biotechnol. 33, 523–531
Jarvis, L. M. (2007) Living on the edge. Drugs targeting the protein Hsp90 push already unstable cancer cells to the brink. Chem. Eng. News 26, 15–23
van Elswijk, D. A. and Irth, H. (2003) Analytical tools for the detection and characterization of biologically active compounds from nature. Phytochem. Rev. 1, 427–439
Vuorela, P., Leinonen, M., Saikku, P., Tammela, P., Rauha, J.-P., Wennberg, T., and Vuorela, H. (2004) Natural products in the process of finding new drug candidates. Curr. Med. Chem. 11, 1375–1389
Potterat, O. (2006) Targeted approaches in natural product lead discovery. Chimia 60, 19–22
Xu, X., Zhu, L., and Chen, L. (2004) Separation and screening of compounds of biological origin using molecularly imprinted polymers. J. Chromatogr. B 804, 61–69
Boldi, A. M. (ed.) (2006) Combinatorial Synthesis of Natural Product-Based Libraries. CRC Press, Taylor & Francis, Boca Raton, FL
Dekker, F. J., Koch, M. A., and Waldmann, H. (2005) Protein structure similarity clustering (PSSC) and natural product structure as inspiration sources for drug development and chemical genomics. Curr. Opin. Chem. Biol. 9, 232–239
Spring, D. R. (2005) Chemical genetics to chemical genomics: small molecules offer big insights. Chem. Soc. Rev. 34, 472–482
Piggott, A. M. and Karuso, P. (2004) Quality, not quantity: the role of natural products and chemical proteomics in modern drug discovery. Comb. Chem. High Throughput Screen. 7, 607–630
Hutchinson, C. R. (2005) Manipulating microbial metabolites for drug discovery and production. In: Zhang, L. and Demain, A. L. (eds.), Natural Products. Drug Discovery and Therapeutic Medicine. Humana, Totowa, NJ, pp. 77–93
Farnet, C. M. and Zazopoulos, E. (2005) Improving drug discovery from microorganisms. In: Zhang, L. and Demain, A. L. (eds.) Natural Products. Drug Discovery and Therapeutic Medicine. Humana, Totowa, NJ, pp. 95–106
Gohil, K. (2002) Genomic responses to herbal extracts: lessons from in vitro and in vivo studies with an extract of Ginkgo biloba. Biochem. Pharmacol. 64, 913–917
Coldre, C. D., Hashim, P., Ali, J. M., Oh, S.-K., Sinskey, A. J., and Rha, C. (2003) Gene expression changes in the human fibroblast induced by Centella asiatica triterpenoids. Planta Med. 69, 725–732
Kawamura, A., Brekman, A., Grigoryev, Y., Hasson, T. H., Takaoka, A., Wolfe, S., and Soll, C. E. (2006) Rediscovery of natural products using genomic tools. Bioorg. Med. Chem. Lett. 16, 2846–2849
Van Lanen, S. G. and Shen, B. (2006) Microbial genomics for the improvement of natural product discovery. Curr. Opin. Microbiol. 9, 252–260
McAlpine, J. B., Bachmann, B. O., Piraee, M., Tremblay, S., Alarco, A.-M., Zazopoulos, E., and Farnet, C. M. (2005) Microbial genomics as a guide to drug discovery and structural Elucidation: ECO-02301, a novel antifungal agent, as an example. J. Nat. Prod. 68, 493–496
Hornung, A., Bertazzo, M., Dziarnowski, A., Schneider, K., Welzel, K., Wohlert, S.-E., Holzenkämpfer, M., Nicholson, G. J., Bechthold, A., Süssmuth, R. D., Vente, A., and Pelzer, S. (2007) A genomic screening approach to the structure-guided identification of drug candidates from natural sources. Chembiochem. 8, 757–766
Martinez, A., Hopke, J., MacNeil, I. A., and Osburne, M. S. (2005) Accessing the genomes of uncultivated microbes for novel natural products. In: Zhang, L. and Demain, A. L. (eds.) Natural Products. Drug Discovery and Therapeutic Medicine. Humana, Totowa, NJ, pp. 295–312
Wenzel, S. C. and Müller, R. (2005) Recent developments towards the heterologous expression of complex bacterial natural product biosynthetic pathways. Curr. Opin. Biotechnol. 16, 594–606
Luesch, H. (2006) Towards high-throughput characterization of small molecule mechanisms of action. Mol. BioSyst. 2, 609–620
Luesch, H., Wu, T. Y., Ren, P., Gray, N. S., Schultz, P. G., and Supek, F. (2005) A genome-wide overexpression screen in yeast for small-molecule target identification. Chem. Biol. 12, 55–63
Luesch, H., Chanda, S. K., Raya, R. M., DeJesus, P. D., Orth, A. P., Walker, J. R., Izpisúa Belmonte, J. C., and Schultz, P. G. (2006) A functional genomics approach to the mode of action of apratoxin A. Nat. Chem. Biol. 2, 158–167
Giaever, G., Shoemaker, D. D., Jones, T. W., Liang, H., Winzeler, E. A., Astromoff, A., and Davis, R. W. (1999) Genomic profiling of drug sensitivities via induced haploinsufficiency. Nat. Genet. 21, 278–283
Lum, P. Y., Armour, C. D., Stepaniants, S. B., Cavet, G., Wolf, M. K., Butler, J. S., Hinshaw, J. C., Garnier, P., Prestwich, G. D., Leonardson, A., Garrett-Engele, P., Rush, C. M., Bard, M., Schimmack, G., Phillips, J. W., Roberts, C. J., and Shoemaker, D. D. (2004) Discovering modes of action for therapeutic compounds using a genome-wide screen of yeast heterozygotes. Cell 116, 121–137
Giaever, G., Flaherty, P., Kumm, J., Proctor, M., Nislow, C., Jaramillo, D. F., Chu, A. M., Jordan, M. I., Arkin, A. P., and Davis, R. W. (2004) Chemogenomic profiling: identifying the functional interactions of small molecules in yeast. Proc. Natl. Acad. Sci. U.S.A. 101, 793–798
Hughes, T. R., Marton, M. J., Jones, A. R., Roberts, C. J., Stoughton, R., Armour, C. D., Bennett, H. A., Coffey, E., Dai, H., He, Y. D., Kidd, M. J., King, A. M., Meyer, M. R., Slade, D., Lum, P. Y., Stepaniants, S. B., Shoemaker, D. D., Gachotte, D., Chakraburtty, K., Simon, J., Bard, M., and Friend, S. H. (2000) Functional discovery via a compendium of expression profiles. Cell 102, 109–126
Brummelkamp, T. R., Fabius, A. M. W., Mullender, J., Madiredjo, M., Velds, A., Kerkhoven, R. M., Bernards, R., and Beijersbergen, R. L. (2006) An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors. Nat. Chem. Biol. 2, 202–206
Espinet, C., Gómez-Arbonés, X., Egea, J., and Comella, J. X. (2000) Combined use of the green and yellow fluorescent proteins and fluorescence-activated cell sorting to select populations of transiently transfected PC12 cells. J. Neurosci. Methods 100, 63–69
Chambers, J. M. and Hastie, T. J. (eds.) (1992) Statistical Models in S. Chapman & Hall/CRC, London
Acknowledgments
H. L. received a Junior Investigator Award (pilot grant) from the University of Florida Shands Cancer Center, American Cancer Society, Institutional Research Grant, ACS-IRG-01–188–01. Further funding to H. L. to study mechanisms of anticancer drug action is provided by the James & Esther King Biomedical Research Program, Grant No. 06-NIR07.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Humana Press
About this protocol
Cite this protocol
Luesch, H., Abreu, P. (2010). A Natural Products Approach to Drug Discovery: Probing Modes of Action of Antitumor Agents by Genome-Scale cDNA Library Screening. In: Roque, A. (eds) Ligand-Macromolecular Interactions in Drug Discovery. Methods in Molecular Biology, vol 572. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-60761-244-5_17
Download citation
DOI: https://doi.org/10.1007/978-1-60761-244-5_17
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-60761-243-8
Online ISBN: 978-1-60761-244-5
eBook Packages: Springer Protocols